ABCB4 and Hepatic fibrosis: In a second study, performed by our group, we evaluated PFIC3 AAV-based gene therapy in FVB Abcb4-/- mice, which have a clinically relevant phenotype characterized by high serum levels of bile salts and transaminases, hepatosplenomegaly, and liver fibrosis [113].